Notícias e Atividades da Dynavax Technologies

Dynavax Technologies é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Dynavax Technologies é uma empresa listada sob o símbolo DVAX (US).

Veja o organograma con seus 31 executivos principais

Biografias mais buscadas da Dynavax Technologies

• Ryan Spencer, Chief Executive Officer and Director
• Brent MacGregor, Director
• Julie Eastland, Director

Recentes movimentos de executivos em Dynavax Technologies

• Justin Burgess, Principal Accounting Officer, deixará a Companhia em 3 de mar. de 2025  (Notícia publicada em 11 de fevereiro de 2025).
• Kelly Macdonald atualmente Senior Vice President and Chief Financial Officer, passará a Senior Vice President, Chief Financial Officer and Principal Accounting Officer em 2 de mar. de 2025  (Notícia publicada em 10 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Dynavax Technologies.

Dynavax Technologies possui 2.339 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Biogen (Estados Unidos).

Popular M&A news in Biotecnologia

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (publicado em 30 de abril de 2025)..
• Deepull acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de abril de 2025).
• Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Herriot Tabuteau - Chief Executive Officer and Director da Axsome Therapeutics
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Dynavax Technologies

• RSS News Feeds | Dynavax Technologies Corporation
• Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October | Dynavax Technologies Corporation
• Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate | Dynavax Technologies Corporation
• Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer | Dynavax Technologies Corporation
• Press Releases | Dynavax Technologies Corporation
• Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine | Dynavax Technologies Corporation
• Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference | Dynavax Technologies Corporation
• Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response | Dynavax Technologies Corporation
• Dynavax Announces Second Quarter 2020 Financial Results | Dynavax Technologies Corporation
• TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales | Dynavax Technologies Corporation
• View more press releases Close

Redes sociais sobre Dynavax Technologies

• Dynavax Technologies na Wikipedia, Google News e Yahoo Finance
• Dynavax Technologies na LinkedIn, Twitter e YouTube